Revuforj®
(revumenib) tablets
25 mg • 110 mg • 160 mg

Revuforj.com

GETTING STARTED ON YOUR REVUFORJ JOURNEY

A guide for patients and caregivers

All images are actor portrayals.

What is Revuforj?

Revuforj® (revumenib) is a prescription medicine used to treat adults and children 1 year and older with acute leukemia with a lysine methyltransferase 2A gene (*KMT2A*) translocation whose disease has come back or has not improved after previous treatment(s).

Your healthcare provider will perform a test to make sure that Revuforj is right for you. It is not known if Revuforj is safe and effective in children less than 1 year of age.

Important Safety Information

What is the most important information I should know about Revuforj?

Revuforj may cause serious side effects, including: Differentiation syndrome. Differentiation syndrome is a serious but common condition that affects your blood cells, which may be life-threatening or lead to death if not treated.

Please see additional Important Safety Information throughout and Full Prescribing Information, including BOXED WARNING, and Medication Guide and Instructions for Use.

GETTING STARTED WITH REVUFORJ

Revuforj is a first-of-its-kind targeted treatment called a menin inhibitor

Revuforj is the only FDA-approved treatment for adults and children 1 year and older who have acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) with a *KMT2A* translocation that has come back or has not improved after previous treatment(s).

How does Revuforj work?

Revuforj is an oral, targeted medication that works differently than chemotherapy. Revuforj works by targeting a protein called **menin** to disrupt interactions with other proteins—specifically KMT2A fusion proteins. These protein interactions are responsible for driving the growth of leukemia cells in people who have AML or ALL with a *KMT2A* translocation.

Targets, binds, and blocks



Revuforj targets and directly binds to menin to help block the source of what drives your specific type of acute leukemia

Individual results may vary.

Please see additional Important Safety Information throughout and Full Prescribing Information, including BOXED WARNING, and Medication Guide and Instructions for Use.

Revuforj may cause serious side effects, including differentiation syndrome

Differentiation syndrome is a serious but common condition that affects your blood cells, which may be life-threatening or lead to death if not treated. Differentiation syndrome has happened as early as 3 days and up to 41 days after starting Revuforj. Tell any healthcare provider caring for you that you are taking a medicine that can cause differentiation syndrome.

Call your healthcare provider or go to the nearest hospital emergency room right away if you develop any of the following symptoms of differentiation syndrome during treatment with Revuforj:

- fever
- cough
- shortness of breath
- severe headache
- confusion
- dizziness or lightheadedness
- fast weight gain
- swelling of arms, legs, neck, groin, or underarm area
- decreased urination

If you develop any of these symptoms of differentiation syndrome, your healthcare provider may start you on a medicine given through a vein (intravenous) called corticosteroids and may monitor you in the hospital.

Click to download the Differentiation Syndrome Wallet Card and keep it with you at all times

CLICK HERE

Share this card with any doctor who is not part of your regular healthcare team, including in the hospital or emergency room, so they are aware that you are taking a medicine that can cause differentiation syndrome.

Revuforj®
(revumenib) tablets
25 mg • 110 mg • 160 mg

A TREATMENT THAT REVOLVES AROUND YOU

Complete remission may be possible with Revuforj

Revuforj was studied in the AUGMENT-101 clinical trial, which included both adult and pediatric patients with acute leukemia with a *KMT2A* translocation whose disease had come back or had not improved after previous treatment(s).

The study was designed to measure the safety and effectiveness of Revuforj

- A total of 104 people from the study met the criteria to be evaluated for effectiveness
- The youngest person was 1 year old and the oldest was 79 years old

~1 in 5 people achieved CR + CRh with Revuforj

In the clinical trial, about **1 in 5** people (22 out of 104, or 21%) achieved complete remission (CR) or complete remission with a partial hematologic recovery (CRh).

- **CR**=signs of acute leukemia are gone, and blood cell counts are back to normal
- **CRh**=signs of acute leukemia are gone but some blood cell counts did not fully return to normal

In the clinical trial, 24 people, or 23%, underwent a stem cell transplant following treatment with Revuforj

Learn more at **Revuforj.com/Results**

Important Safety Information (*cont'd*)

Revuforj may cause serious side effects, including:

- **Changes in electrical activity of your heart called QT prolongation.** QT prolongation is a serious but common side effect that can cause irregular heartbeats that can be life-threatening or lead to death. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) and will also do blood tests to check your potassium and magnesium levels before and during treatment with Revuforj. Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or if you feel your heart beating irregularly or fast during treatment with Revuforj.

Please see additional Important Safety Information throughout and Full Prescribing Information, including BOXED WARNING, and Medication Guide and Instructions for Use.

Revuforj® (revumenib) tablets
25 mg • 110 mg • 160 mg

WHAT TO KNOW BEFORE TAKING REVUFORJ

Revuforj tablets come in different strengths. Each strength is a different color:

25 mg **110 mg** **160 mg**

Bottles and tablets shown are not actual size.

Your healthcare provider may prescribe more than 1 strength of Revuforj tablets for you, so it is important that you understand how to take your medicine the right way. Be sure that you understand exactly how many tablets you need to take, and what strengths to take.

Take Revuforj exactly as your healthcare provider tells you to. Do not change your dose or stop taking Revuforj unless your healthcare provider tells you to.

How to store Revuforj

- Store Revuforj at room temperature between 68°F to 77°F (20°C to 25°C)
- Keep the tablets in the bottle that it comes in until you are ready to take it
- The Revuforj bottle has a drying agent (desiccant) and child-resistant closure

Keep Revuforj and all medicines out of reach of children

Before taking Revuforj, tell your healthcare provider about all your medical conditions, including if you:

- have any heart problems, including a condition called long QT syndrome
- have been told you have low blood levels of potassium or magnesium
- are pregnant or plan to become pregnant. Revuforj can harm your unborn baby
- are breastfeeding or plan to breastfeed. It is not known if Revuforj passes into your breast milk. Do not breastfeed during your treatment with Revuforj or for 1 week after your last dose of Revuforj

Please see additional Important Safety Information throughout and Full Prescribing Information, including BOXED WARNING, and Medication Guide and Instructions for Use.

Revuforj® (revumenib) tablets
25 mg • 110 mg • 160 mg

CONVENIENCE OF AN ORAL MEDICINE YOU CAN TAKE AT HOME

How to take Revuforj

2 times a day by mouth

Take at about the same time each day (about 12 hours apart)

On an empty stomach

In the clinical trial, this was defined as at least 2 hours after a meal and 1 hour before the next meal

OR

With a low-fat meal

Low-fat meals should be about 400 calories and contain 25% or less fat

- Swallow Revuforj tablets whole with a cup of water
- **Do not** cut or chew tablets
- If you are unable to swallow tablets, Revuforj can be crushed and dispersed in water as directed in the **Instructions for Use**.
  - See the **Instructions for Use** for detailed information on how to prepare and give Revuforj

If you miss a dose of Revuforj or did not take it at the usual time, take your dose as soon as possible and at least 12 hours before your next dose. **Do not** take 2 doses within 12 hours. Return to your normal scheduled dose the following day.

Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Revuforj and other medicines may affect each other, causing side effects.

Please see additional Important Safety Information throughout and Full Prescribing Information, including BOXED WARNING, and Medication Guide and Instructions for Use.

CLICK HERE

Find helpful tools and resources that are designed to help you stay informed and feel supported as you or your loved one begins treatment with Revuforj.

Revuforj.com/support-resources

Revuforj®
(revumenib) tablets
25 mg • 110 mg • 160 mg

POSSIBLE SIDE EFFECTS OF REVUFORJ

Revuforj may cause serious side effects, including differentiation syndrome, which may be life-threatening or lead to death if not treated

For more information about differentiation syndrome and a list of symptoms, please see page 3 of this brochure.

Revuforj may also cause changes in electrical activity of your heart, called "QT prolongation"

QT prolongation is a serious but common side effect that can cause irregular heartbeats that can be life-threatening or lead to death. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) and will also do blood tests to check your potassium and magnesium levels before and during treatment with Revuforj.

Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or if you feel your heart beating irregularly or fast during treatment with Revuforj.

Revuforj can cause harm to your unborn baby

Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Revuforj.

Females who are able to become pregnant: your healthcare provider will perform a pregnancy test within 7 days before you start treatment with Revuforj. You should use effective birth control (contraception) during treatment with Revuforj and for 4 months after the last dose of Revuforj.

Males who have female partners who are able to become pregnant should use effective birth control during treatment with Revuforj and for 4 months after the last dose of Revuforj.

Talk to your healthcare provider about birth control methods you can use during this time. Revuforj may cause fertility problems in females and males. Talk to your healthcare provider if this is a concern for you.

It is not known if Revuforj passes into your breast milk. **Do not** breastfeed during your treatment with Revuforj or for 1 week after your last dose of Revuforj.

The most common side effects of Revuforj include:

- bleeding (hemorrhage)
- nausea and vomiting
- muscle pain
- infections, including bacterial and viral infections
- low white blood cell counts with fever
- diarrhea
- changes in liver function tests
- swelling in the arms and legs
- decreased appetite
- constipation
- tiredness

Your healthcare provider will do blood tests and ECGs before you start and during treatment with Revuforj

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with Revuforj if you develop certain side effects.

These are not all the possible side effects of Revuforj. Call your healthcare provider for medical advice about side effects.

You are encouraged to report side effects of prescription drugs to FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088

Please see additional Important Safety Information throughout and Full Prescribing Information, including BOXED WARNING, and Medication Guide and Instructions for Use.

Revuforj® (revumenib) tablets
25 mg • 110 mg • 160 mg

CAREGIVER CORNER

If you are caring for a loved one who is taking Revuforj, visit our website page that is dedicated to providing tips and support for the treatment journey ahead.

Revuforj.com/Caregiver-Corner

Revuforj®
(revumenib) tablets
25 mg • 110 mg • 160 mg

Please see additional Important Safety Information throughout and Full Prescribing Information, including BOXED WARNING, and Medication Guide and Instructions for Use.

The information provided here is not a substitute for talking with your healthcare provider. Your healthcare provider is the best source of information about your disease.

All individuals depicted are models used for illustrative purposes only, unless otherwise noted.

Syndax